Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of Reparixin for severe COVID-19 pneumonia
2020-005919-51Phase 3Completed
- Sponsor
- Dompé
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus pneumonia and Coronavirus disease 2019 pneumonia comparing Reparixin arm with Placebo arm (2 arms). Primary endpoint: Time to composite endpoint of progression or death up to 28 days. Started Jan 2021; status: completed.
02
Drugs
reparixin
03
Conditions
coronavirus pneumoniaCoronavirus disease 2019 pneumonia
Beyond the preview
Go deeper on 2020-005919-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005919-51.